Dyne Plots Path for Rare Muscle Disease Candidate Dyne Therapeutics also provided an encouraging program update at JPM25 on Wednesday, giving what Jefferies analysts call a “bar for success” that ...

In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report), with a price target of $52.00. Discover outperforming stocks ...

He soon found himself in Vietnam as one of two officers leading 12 enlisted sailors in SEAL Team 1. Three months after Kerrey's arrival in South Vietnam in January 1969, his team was tasked with ...

On Friday, Dyne Therapeutics, Inc. DYN revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Dyne plans to begin a global ...

Investing.com -- Shares of Dyne Therapeutics, Inc. (Nasdaq: DYN) plummeted 25% as the biotechnology firm reported early trial data for its experimental therapy for myotonic dystrophy type 1 (DM1 ...

(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Myotonic ...